LYON, France, 10th May2007 – New clinical study results confirm the high and sustained efficacy of Gardasil® in the prevention of cervical cancer and other Human Papillomavirus related diseases that occur before cervical cancer and beyond the cervix. After three years of follow up in the large phase III clinical studies FUTURE I and II, which included more than 17,000 women, Gardasil® prevented 98% to 100% of pre-cancerous and potentially pre-cancerous cervical lesions (CIN 1-3), pre-cancerous and potentially pre-cancerous vulvar and vaginal lesions (VaIN 1-3 and VIN 1-3), and genital warts caused by Human Papillomavirus types 6, 11, 16 and 18. The results were published today in the New England Journal of Medicine (NEJM).
